Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. COVID-19 in people with multiple sclerosis: A global data sharing initiative

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Predictors of treatment outcome in patients with paediatric onset multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Reproductive history of the Danish multiple sclerosis population: A register-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Biomarkers of inflammation and epithelial barrier function in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Dimethyl fumarate (DMF) is a disease-modifying therapy used for patients with relapsing-remitting multiple sclerosis (RRMS). B cells are important contributors to the pathogenesis of RRMS, where they regulate the inflammatory immune responses and participate in development of lesions in the central nervous system (CNS). The impact of DMF on B cell subpopulations remains incompletely understood.

OBJECTIVES: In this study, we evaluated the effects of DMF on B cell subpopulations and their effector functions.

METHODS: Blood from 21 DMF-treated and 18 untreated patients with RRMS was analyzed by flow cytometry.

RESULTS: We found that DMF reduces the frequency of circulating antigen-experienced B cells, a reduction likely related to a reduced frequency of follicular helper T (TFH) cells and an increased frequency of follicular regulatory T (TFR) cells. Studying the impact of monomethyl fumarate (MMF), the primary metabolite of DMF, on B cell effector function in vitro showed that MMF increased the frequency of transforming growth factor (TGF)-β-producing B cells and decreased the frequency of B cells secreting lymphotoxin (LT)-α, tumor necrosis factor (TNF)-α, interleukin (IL)-6, and to a lesser extent IL-10.

CONCLUSION: In summary, these data suggest an anti-inflammatory role of DMF and its metabolite MMF on the B cell compartment.

OriginalsprogEngelsk
TidsskriftMultiple sclerosis
Vol/bind25
Udgave nummer9
Sider (fra-til)1289-1297
Antal sider9
ISSN1352-4585
DOI
StatusUdgivet - aug. 2019

ID: 58577613